Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer

(2019) Brandon A. Dyer et al.   Journal of the National Comprehensive Cancer Network

Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.

(2018) Hyun Cheol Chung et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy

(2016) Kristina H. Young et al.   PLoS One

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

(2015) Andrew B Sharabi et al.   LANCET ONCOLOGY

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

(2014) S. J. Dovedi et al.   CANCER RESEARCH

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Significance of Histology and Positive Lymph Node Involvement Following Radical Hysterectomy in Carcinoma of the Cervix

(2009) O Kenneth Macdonald et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment

(2009) Y. Lee et al.   BLOOD